Overview

* SAGE Therapeutics Q2 collaboration revenue from ZURZUVAE rises 68% from Q1 2025

* Company's acquisition by Supernus Pharmaceuticals expected to close in Q3 2025

* Net loss for Q2 2025 was $49.7 mln, cash position at $366 mln

Outlook

* Company anticipates investments will help topline revenue growth in 2025

* SAGE-319 Phase 1 study data expected by late 2025

* Company to update on SAGE-324 indications by mid-2025

* Supernus acquisition expected to close in Q3 2025

Result Drivers

* ZURZUVAE REVENUE - Collaboration revenue from ZURZUVAE increased 68% from Q1 2025, driven by commercialization efforts

* PRESCRIPTION GROWTH - Over 4,000 prescriptions shipped in Q2 2025, a 36% increase from Q1 2025

* OBGYN PRESCRIBERS - OBGYNs accounted for 80% of all prescriptions in Q2 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $23.21

Product mln

Revenue

Q2 Net -$49.65

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 14 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for SAGE Therapeutics Inc ( SAGE ) is $8.50, about 2.4% below its July 29 closing price of $8.70

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)